
Michael A Iacocca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11164227/publications.pdf Version: 2024-02-01



MICHAEL A LACOCCA

#	Article	IF	CITATIONS
1	Improving reporting standards for polygenic scores in risk prediction studies. Nature, 2021, 591, 211-219.	13.7	265
2	Severe hypertriglyceridemia is primarily polygenic. Journal of Clinical Lipidology, 2019, 13, 80-88.	0.6	136
3	ClinVar database of global familial hypercholesterolemiaâ€associated DNA variants. Human Mutation, 2018, 39, 1631-1640.	1.1	84
4	Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia. Journal of Lipid Research, 2017, 58, 2202-2209.	2.0	65
5	Recent advances in genetic testing for familial hypercholesterolemia. Expert Review of Molecular Diagnostics, 2017, 17, 641-651.	1.5	53
6	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. Genetics in Medicine, 2022, 24, 293-306.	1.1	53
7	Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias. BMC Medical Genomics, 2020, 13, 23.	0.7	52
8	Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1316-1324.	0.8	34
9	ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG/AMP guidelines. Genome Medicine, 2022, 14, 6.	3.6	34
10	Role of DNA copy number variation in dyslipidemias. Current Opinion in Lipidology, 2018, 29, 125-132.	1.2	33
11	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. Journal of Lipid Research, 2018, 59, 1529-1535.	2.0	22
12	Progress in finding pathogenic DNA copy number variations in dyslipidemia. Current Opinion in Lipidology, 2019, 30, 63-70.	1.2	18
13	Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia. CJC Open, 2019, 1, 225-230.	0.7	10
14	Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia. CJC Open, 2019, 1, 115-118.	0.7	8